Nadine Dohollou
Polyclinique de Bordeaux-Tondu(FR)
Publications by Year
Research Areas
Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, BRCA gene mutations in cancer, Cancer Treatment and Pharmacology, Radiomics and Machine Learning in Medical Imaging
Most-Cited Works
- → Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer(2021)702 cited
- → Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients.(1998)120 cited
- → New advances in DPYD genotype and risk of severe toxicity under capecitabine(2017)102 cited
- → Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial(2022)67 cited
- → Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.(1998)53 cited
- → Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study(2019)52 cited
- → Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients(2017)46 cited
- → COVID-19 et personnes suivies pour un cancer du sein : recommandations françaises pour la pratique clinique de Nice-St Paul de Vence, en collaboration avec le Collège Nationale des Gynécologues et Obstétriciens Français (CNGOF), la Société d’Imagerie de la Femme (SIFEM), la Société Française de Chirurgie Oncologique (SFCO), la Société Française de Sénologie et Pathologie Mammaire (SFSPM) et le French Breast Cancer Intergroup-UNICANCER (UCBG)(2020)41 cited
- → Abstract GS3-05: Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial(2022)31 cited
- → Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA(2020)31 cited